Blog posts by Sophie Cairns
8 June 2017 by
There is increasing public debate over whether Hong Kong’s cash-rich government should give more public funding to...
14 September 2016 by Sophie Cairns
Japan’s Ministry of Foreign Affairs issued an unusually direct warning of “great turmoil” in a post-Brexit scenario
1 August 2016 by Sophie Cairns
A win that is bittersweet
1 June 2016 by Sophie Cairns
Pricing and cost-effectiveness and public hospital discussions from our trip to Asia
3 December 2015 by Sophie Cairns
Vietnam’s pharmaceutical sector is expected to see the fiercest competition
20 October 2015 by Sophie Cairns
In Hong Kong’s flourishing black market, costly branded drugs can be bought at a fraction of their market price
19 August 2015 by Sophie Cairns
IHS Life Sciences expects the explosion to cause significant disruption to the shipment of non-time-sensitive...
8 July 2015 by Sophie Cairns
Thailand's battle against runaway pharmaceutical prices.
23 April 2015 by Sophie Cairns
A look at China’s CFDA new regulations on far-flung corners of its pharmaceutical sector: multi-regional clinical trials,...
19 December 2014 by Sophie Cairns
Last month, media reports surfaced over a missive that China’s central pricing authority had issued to provincial...
4 September 2014 by Sophie Cairns
About the Life Sciences BlogIndustry insights from the IHS Markit Life Sciences team covering market access, pricing and reimbursement, emerging markets, generics strategies, therapeutic development pathways, forecasting and market sizing, and general competitive intelligence. IHS Markit Blog Home »
Tweets by @IHS4LifeScience